Altre lingue 2seventy bio, Inc.

Azioni

TSVT

US9013841070

Tempo differito Nasdaq Altri mercati azionari 19:00:00 03/07/2024			Variaz. 5gg	Var. 1 gen.
4,01 ^USD	+3,89%		+11,39%	-6,09%

26/06	2seventy bio vende il candidato per l'Emofilia A e la tecnologia di editing genico a Novo Nordisk; le azioni salgono dopo le ore.	MT
10/06	Transcript : 2seventy bio, Inc. Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-10-2024 01:20 PM

Altre lingue

Sblocca tutte le notizie: sii il primo a essere informato e reagisci prima dei mercati!

Registrazione 100% gratuita

2seventy bio Sells Hemophilia A Candidate, Gene Editing Technology to Novo Nordisk; Shares Rise After Hours	26/06
2seventy Bio Sells Gene Editing Therapy To Novo Nordisk for Up To $40 Million	26/06
2seventy bio Announces Sale of Hemophilia A Candidate and MegaTAL In Vivo Gene Editing Technology to Novo Nordisk for up to $40 million	26/06
Top Midday Decliners	06/06
2seventy bio to Participate in Upcoming Investor Conferences	23/05
Earnings Flash (TSVT) 2SEVENTY BIO Reports Q1 Revenue $12.4M, vs. Street Est of $14.1M	08/05
2seventy bio Reports First Quarter Financial Results and Recent Operational Progress	08/05
2seventy bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	08/05
2seventy bio to Report First Quarter 2024 Financial Results on May 8, 2024	06/05
2seventy bio to Report First Quarter 2024 Financial Results on May 8, 2024	03/05
US FDA mandates label updates on CAR-T cancer therapies	19/04
FDA Approves BMS And J&J CAR-T Cell Therapies For The Earlier Treatment Of Multiple Myeloma	17/04
Engine Capital Withdraws Nominations to 2seventy bio Board	09/04
U.S. FDA Approves Bristol Myers Squibb and 2seventy bio's Abecma for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma after Two Prior Lines of Therapy	08/04
Bristol-Myers Squibb, 2seventy Bio Say FDA Approves Expansion of Myeloma Treatment's Indication	05/04
Bristol Myers, 2seventy Get FDA OK for Earlier Abecma Use in Multiple Myeloma	05/04
Bristol Myers : la FDA valide Abecma dans le myélome multiple	05/04
US FDA allows expanded use of Bristol Myers' cell therapy for blood cancer	05/04
U.S. FDA allows expanded use of Bristol Myers' cell therapy	05/04
U.S. Fda Approves Bristol Myers Squibb and 2Seventy Bio?S Abecma for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma After Two Prior Lines of Therapy	05/04

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue 2seventy bio, Inc.

Azioni

TSVT

US9013841070

Altre lingue

Filtri